UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
SCHEDULE 14A INFORMATION
INFORMATION STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. ___)
Filed by the registrant [X]
Filed by a party other than the registrant [ ]
Check the appropriate box:
[ ] Preliminary Information Statement
[ ] Confidential, for use of the Commission only (as permitted by Rule
14a-6(e)(2)).
[ ] Definitive proxy statement.
[X] Definitive additional materials.
[ ] Soliciting material under Rule 14a-12.
ENDOVASC, INC.
(Name of Registrant as Specified in its Charter)
------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth amount on which
filing fee is calculated and state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offering fee was
paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of the filing.
1) Amount previously paid:
2) Form, Schedule or Registration Statement No.:
3) Filing Party:
4) Date Filed:
E. MICHAEL PRATER RESIGNS AS DIRECTOR OF ENDOVASC, INC.
MONTGOMERY, TX - BUSINESS WIRE - NOVEMBER 5, 2004 - ENDOVASC, INC. (OTCDB: EVSC
- - NEWS), a business development company focused on innovative drug development,
announced that E. Michael Prater resigned from the Company's Board of Directors.
Mr. Prater was recently elected to the Board of Directors to fill a vacancy
created by the expansion of the Board from three to five members. After
expressing his regrets, Mr. Prater indicated that his personal obligations for
the upcoming year would make it impossible for him to fulfill his
responsibilities as a Director of Endovasc, Inc. The Company immediately took
action to reduce the number of directors that make up the full Board of
Directors from five members to four members.
Endovasc, Inc. will hold its Annual Meeting of Stockholders on November 19, 2004
at Havens Landing in Montgomery, Texas. One of the items on the Agenda for the
Annual Meeting is the reelection of M. Dwight Cantrell as a member of the Board
of Directors. Other directors that will continue to serve following the Annual
Meeting are Dr. Diane Dottavio, Barbara J. Richardson and Donald Leonard. "We
encourage all of our stockholders to sign and return a proxy so that their vote
can be counted at our Annual Meeting," said Dr. Diane Dottavio, Chief Executive
Officer of the Company.
About Endovasc, Inc.
Endovasc, Inc., established in 1996, is a business development company focused
on innovative drug development in the areas of cardiovascular and metabolic
medicine. Endovasc subsidiaries include Liprostin, Inc., which holds the
intellectual property for liposomal based treatment to increase circulation and
reduce leg pain in patients suffering from vascular disease; Angiogenix Limited,
Inc., which possesses the sublicense for an isomer of nicotine that has been
shown to be beneficial in the treatment of chronic myocardial aschemia; and
Nutraceutical Development Corporation, which is developing nutraceutical
products using the company's other technologies.
For more information about Endovasc, please visit www.Endovasc.com
----------------
Contact: Investor Relations for Endovasc, Inc.
David Zazoff, 212-505-5976
www.PressReleases@za-Consulting.net
-----------------------------------